European Clinical Trial Finds Drug Sulthiame Reduces Sleep Apnea Breathing Interruptions by Up to 47%

For the roughly one billion people worldwide who live with obstructive sleep apnea, the treatment options have remained stubbornly limited for decades. CPAP machines work well when people use them consistently — which many don't. Surgical options exist but are invasive and not always effective. A new clinical trial out of Europe is now generating genuine excitement about a third path: a pill. Sulthiame, a drug that has been used to treat epilepsy for over half a century, significantly reduced breathing interruptions in moderate to severe sleep apnea patients, with those on higher doses experiencing up to 47 percent fewer pauses in breathing per hour of sleep.

What Sulthiame Does and Why It Works for Apnea

Sulthiame belongs to a class of drugs called carbonic anhydrase inhibitors. Its primary therapeutic mechanism in epilepsy involves reducing abnormal electrical activity in the brain — but its effect on breathing is what makes it relevant to sleep apnea research. The drug stimulates the respiratory drive, essentially prompting the body to breathe more reliably and consistently. Sleep apnea at its core is a failure of the upper airway to stay open during sleep, often compounded by an unstable respiratory control system. Sulthiame appears to address the control system component in a way that reduces the frequency and severity of apnea events.

This isn't the first time carbonic anhydrase inhibitors have been explored for sleep-disordered breathing — acetazolamide has been studied in similar contexts for years. What distinguishes sulthiame in this trial is the size of the effect at the doses tested and the improvement in blood oxygen levels during sleep, which is the downstream metric that actually connects sleep apnea to the cardiovascular and cognitive consequences that make the condition medically serious.

The Trial Design and What It Found

The European trial enrolled patients with moderate to severe obstructive sleep apnea — a population where the clinical stakes are higher and the need for effective treatment is most urgent. Participants were randomized to receive different doses of sulthiame or placebo, with sleep quality measured using standard polysomnography — the overnight sleep study that tracks breathing events, oxygen saturation, brain activity, and other physiological markers. The primary endpoint was the apnea-hypopnea index, which counts the number of breathing interruptions per hour of sleep.

Patients on higher doses saw their apnea-hypopnea index drop by up to 47 percent compared to baseline. That's a clinically meaningful reduction — enough to shift some patients from the severe category into the moderate range, or from moderate into mild, which changes both their symptoms and their long-term health risk profile. Blood oxygen levels improved as well, suggesting that the breathing interruptions that did occur were shorter and less severe, not simply less frequent.

Why a Pill Would Change Everything for Patients

CPAP therapy — continuous positive airway pressure delivered through a mask worn during sleep — is the established gold standard for sleep apnea treatment. It works extremely well for patients who tolerate it. The problem is adherence. Studies consistently show that a substantial portion of CPAP-prescribed patients either abandon the therapy within months or use it for fewer hours per night than is therapeutically effective. The mask is uncomfortable, the machine is loud, it complicates travel, and it's disruptive to bed partners. These are not trivial barriers.

A pharmacological treatment that patients can take as a daily pill would sidestep all of those adherence barriers entirely. Even if a drug produces somewhat smaller breathing improvements than optimal CPAP use, it may generate better real-world outcomes simply because patients will actually take a pill consistently in ways they won't consistently wear a mask. That tradeoff is already being discussed by sleep medicine specialists as the sulthiame results circulate.

What Comes Next Before Sulthiame Reaches Patients

The trial results are promising, but promising phase two or phase three data is not the same as an approved treatment. Sulthiame will need to complete the full regulatory pathway before it can be prescribed for sleep apnea — separate from its existing epilepsy approvals, since the indication, dosing, and patient population are different. That process typically takes several years and requires additional trial data confirming efficacy and, crucially, long-term safety at the doses needed for sleep apnea treatment.

The side effect profile will receive particular scrutiny. Carbonic anhydrase inhibitors are generally well-tolerated but can cause side effects including tingling sensations, fatigue, and metabolic changes. Whether those effects are acceptable in a sleep apnea population — which is broader and generally less medically monitored than an epilepsy population — is a question the regulatory review will need to answer carefully. If the safety profile holds at therapeutic doses for apnea, sulthiame could represent the most significant shift in sleep apnea treatment options in a generation.